Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Accumulated Expenses: 2022-2024

Historic Accumulated Expenses for Corvus Pharmaceuticals (CRVS) over the last 3 years, with Dec 2024 value amounting to $3.7 million.

  • Corvus Pharmaceuticals' Accumulated Expenses rose 35.73% to $5.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.7 million, marking a year-over-year increase of 35.73%. This contributed to the annual value of $3.7 million for FY2024, which is 6.17% down from last year.
  • According to the latest figures from FY2024, Corvus Pharmaceuticals' Accumulated Expenses is $3.7 million, which was down 6.17% from $4.0 million recorded in FY2023.
  • Corvus Pharmaceuticals' 5-year Accumulated Expenses high stood at $7.5 million for FY2022, and its period low was $3.7 million during FY2024.
  • Moreover, its 3-year median value for Accumulated Expenses was $4.0 million (2023), whereas its average is $5.1 million.
  • Data for Corvus Pharmaceuticals' Accumulated Expenses shows a maximum YoY tumbled of 47.40% (in 2023) over the last 5 years.
  • Yearly analysis of 3 years shows Corvus Pharmaceuticals' Accumulated Expenses stood at $7.5 million in 2022, then tumbled by 47.40% to $4.0 million in 2023, then decreased by 6.17% to $3.7 million in 2024.